Trial Profile
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Vadastuximab talirine (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 08 May 2018 Status changed from suspended to completed.
- 25 Jun 2017 Cohort results from this trial presented at the 22nd Congress of the European Haematology Association
- 19 Jun 2017 According to a company media release, Seattle Genetics is suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials based on unfavourable results obtained in the phase III CASCADE trial.